Rank #1506RCUS

Arcus Biosciences, Inc.

$19.48

0.26% (Daily)

Market Cap

$2.41B

Revenue

$240.00M

Rank by MCap

#1506

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Terry J. Rosen Ph.D.

Headquarters

Hayward, CA

Employees

627

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine path...